Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection

Marc Bourlière(Universität Hamburg), Stefan Zeuzem(Goethe University Frankfurt), Ziad Younes(American College of Veterinary Surgeons), Meena B. Bansal(Mount Sinai Hospital), Alnoor Ramji(Universität Hamburg), Myron J. Tong(Huntington Medical Research Institutes), Hadas Dvory‐Sobol(Gilead Sciences (United States)), Charles Landis(University of Washington), K. Rajender Reddy(Hospital of the University of Pennsylvania), Elizabeth C. Verna(Columbia University Irving Medical Center), Eugene R. Schiff(University of Miami), Stuart C. Gordon(United States Department of Veterans Affairs), Victor de Lédinghen(Hôpital Cardiologique du Haut-Lévêque), Michael P. Curry, John G. McHutchison(Gilead Sciences (United States)), Luisa M. Stamm(Merck & Co., Inc., Rahway, NJ, USA (United States)), Steven L. Flamm(Northwestern University), Peter Buggisch(Institute for Interdisciplinary Medicine), Natarajan Ravendhran(University of Florida), Simone I. Strasser(University of Padua), Simon C. Ling(University of Toronto), G. Mani Subramanian(Pacific Biosciences (United States)), Kris V. Kowdley(Liver Institute Northwest), Jie Zhang(Universität Hamburg), Tram T. Tran(Cedars-Sinai Medical Center), Diana M. Brainard(Gilead Sciences (United States)), Evguenia S. Svarovskaia(University of Miami), Stephen Pianko(Universität Hamburg), M.P. Manns(Universität Hamburg), Curtis Cooper(Universität Hamburg), Robert H. Hyland(Gilead Sciences (United States)), Kaijiao Huang(Universität Hamburg)
New England Journal of Medicine
May 31, 2017
Cited by 565


Related Papers